ASXChange of Director's Interest Notice x4
director_dealing announcement
BLINKLAB LIMITED ORDINARY (BB1) News
Latest articles and price-sensitive announcements with AI sentiment classification.
KalkineBlinkLab Limited Grants 2.5 Million Unquoted Options to Key Executives and Consultants
BlinkLab Limited has announced the allocation of 2.5 million unquoted options under its employee incentive program. These options, which are not intended for ASX quotation, carry an exercise price of $0.975 and expire on July 13, 2029. This initiative is designed to motivate key management personnel and consultants as part of BlinkLab's strategic incentives. Key Points BlinkLab Limited (BB1) Issued 2.5 million unquoted options exercisable at $0.975, expiring July 13, 2029 Options granted to k...
BlinkLab Limited Announces New Quoted Securities Issuance Complying with Section 708A(5) of Corporations Act 2001
BlinkLab Limited has revealed the issuance of new quoted securities in their recent company update. Filed on 13 July 2026, the notice confirms adherence to key provisions of the Corporations Act 2001. This update is significant for investors tracking BlinkLab's regulatory compliance and governance practices. Key Points BlinkLab Limited (BB1) Issued new quoted securities under Section 708A(5) of the Corporations Act 2001 Confirmed compliance with Chapter 2M and Sections 674 and 674A of the Act...
Notification regarding unquoted securities - BB1
other announcement
Google NewsBlinkLab (ASX:BB1) Drops as Early-Stage Health-Tech Sentiment Turns Volatile - Kalkine
BlinkLab (ASX:BB1) Drops as Early-Stage Health-Tech Sentiment Turns Volatile Kalkine
Notification regarding unquoted securities - BB1
other announcement
BB1 Partners with ESPOCH on Large-Scale Multicenter Program
other announcement
Therapy Evaluation for Neurodevelopmental Conditions
other announcement
BB1 to present at Stocks in the Vines Investor Access Day
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
BlinkLab Invited to Present at Ignite Investment Summits
other announcement
Is (ASX:BB1) Entering a New Phase in Digital Diagnostics?
Highlights Fresh capital fuels clinical and regulatory progress Smartphone-based diagnostics advancing toward global rollout Expansion into broader neurodevelopmental screening pipeline BlinkLab is strengthening its clinical and regulatory journey with new funding, advancing its diagnostic platforms while expanding into new healthcare markets across multiple regions. A Strategic Capital Boost for Clinical Momentum Digital health innovator BlinkLab (ASX:BB1) has taken a notable step forw...
BlinkLab Secures A$17.5M to Launch Autism Diagnostic Aid
other announcement
Will BlinkLab (ASX:BB1) Spend Its Cash Wisely? - simplywall.st
Will BlinkLab (ASX:BB1) Spend Its Cash Wisely? simplywall.st
Small CapsValidation Program Commences-FDA 510(k) - First Participant
other announcement
Morocco's Nationwide Government-Funded Autism Screening
other announcement
Clinical Trial Network for Pivotal FDA Study Complete
other announcement
BlinkLab Forms Partnership with SHANK2 Autism Foundation
other announcement
Notification regarding unquoted securities - BB1
other announcement
BB1 Expands Pivotal FDA Trial Network to Nine Elite Sites
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
BB1 Presents at Simons Foundation Autism Research Initiative
other announcement
BlinkLab Receives $822k R&D Tax Incentive Refund
other announcement
High-Profile Journal Publication Validates BB1 Technology
other announcement
Appointment of Managing Director and Board Changes
other announcement
Rush University Medical Center joins Pivotal US Autism Trial
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement